EFFECTIVE ANTIBODY RESPONSE OF AFRICAN WILD DOGS (LYCAON PICTUS) TO CANINE DISTEMPER VACCINATION WITH A LIVE ATTENUATED VACCINE.

IF 0.7 4区农林科学 Q3 VETERINARY SCIENCES

Journal of Zoo and Wildlife Medicine Pub Date : 2025-03-01 DOI:10.1638/2023-0088

Robin Gieling, Anne Schmidt-Küntzel, Karina Flores-Pineda, Mick Bailey, Nicola Rooney, Laurie Marker

{"title":"EFFECTIVE ANTIBODY RESPONSE OF AFRICAN WILD DOGS (LYCAON PICTUS) TO CANINE DISTEMPER VACCINATION WITH A LIVE ATTENUATED VACCINE.","authors":"Robin Gieling, Anne Schmidt-Küntzel, Karina Flores-Pineda, Mick Bailey, Nicola Rooney, Laurie Marker","doi":"10.1638/2023-0088","DOIUrl":null,"url":null,"abstract":"Vaccinating African wild dogs (Lycaon pictus) against canine distemper virus (CDV) using live attenuated vaccines (LAV) has been controversial because of limitations in the vaccines' effectiveness and safety. However, CDV is a significant pathogen for African wild dogs, and CDV LAV are currently the only vaccines readily available on the African continent, making them a crucial tool for in situ conservation. There are few studies exploring immunogenicity of CDV LAV, and even less information pertaining to optimal vaccination protocols. This study reports the use of CDV LAV VanguardTM Plus 5/L in 16 African wild dogs from two sibling groups with initial inoculation at approximately 6-7 wk of age. The majority (81%, n = 13) of pups generated protective titers after initial vaccination. One pup died of CDV-suspected neurological disease within 17 d of initial vaccination. All remaining dogs received a second dose, and 100% of those achieved protective immunity (as per domestic dog reference values). Protective antibody titers were maintained throughout the sampling period of 284 and 373 d from the second vaccination. The risk of possible vaccine-induced disease cannot be excluded, but may be a sustainable risk compared with the protective potential of CDV LAV for African wild dogs.","PeriodicalId":17667,"journal":{"name":"Journal of Zoo and Wildlife Medicine","volume":"56 1","pages":"148-153"},"PeriodicalIF":0.7000,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Zoo and Wildlife Medicine","FirstCategoryId":"97","ListUrlMain":"https://doi.org/10.1638/2023-0088","RegionNum":4,"RegionCategory":"农林科学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"VETERINARY SCIENCES","Score":null,"Total":0}

引用次数: 0

Abstract

Vaccinating African wild dogs (Lycaon pictus) against canine distemper virus (CDV) using live attenuated vaccines (LAV) has been controversial because of limitations in the vaccines' effectiveness and safety. However, CDV is a significant pathogen for African wild dogs, and CDV LAV are currently the only vaccines readily available on the African continent, making them a crucial tool for in situ conservation. There are few studies exploring immunogenicity of CDV LAV, and even less information pertaining to optimal vaccination protocols. This study reports the use of CDV LAV Vanguard^TM Plus 5/L in 16 African wild dogs from two sibling groups with initial inoculation at approximately 6-7 wk of age. The majority (81%, n = 13) of pups generated protective titers after initial vaccination. One pup died of CDV-suspected neurological disease within 17 d of initial vaccination. All remaining dogs received a second dose, and 100% of those achieved protective immunity (as per domestic dog reference values). Protective antibody titers were maintained throughout the sampling period of 284 and 373 d from the second vaccination. The risk of possible vaccine-induced disease cannot be excluded, but may be a sustainable risk compared with the protective potential of CDV LAV for African wild dogs.

查看原文本刊更多论文

非洲野狗（lycaon pictus）对犬瘟热减毒活疫苗接种的有效抗体反应。

使用非洲野狗（Lycaon pictus）接种犬瘟热病毒（CDV）减毒活疫苗（LAV）一直存在争议，因为疫苗的有效性和安全性存在局限性。然而，CDV是非洲野狗的重要病原体，CDV LAV是目前非洲大陆上唯一现成的疫苗，这使它们成为就地保护的重要工具。关于CDV - LAV免疫原性的研究很少，关于最佳疫苗接种方案的信息就更少了。本研究报告了来自两个兄弟群的16只非洲野狗在大约6-7周龄时首次接种CDV LAV VanguardTM Plus 5/L。大多数（81%,n = 13）幼犬在初次接种疫苗后产生了保护效价。1只幼犬在初次接种疫苗后17天内死于疑似cdv的神经系统疾病。所有剩余的狗都接受了第二剂，100%的狗获得了保护性免疫（根据家犬参考值）。保护性抗体滴度在第二次接种后的284和373 d的采样期内保持不变。不能排除可能的疫苗引起疾病的风险，但与CDV LAV对非洲野狗的保护潜力相比，这可能是一种可持续的风险。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Journal of Zoo and Wildlife Medicine 农林科学-兽医学

CiteScore

1.70

自引率

14.30%

发文量

审稿时长

9-24 weeks

期刊介绍： The Journal of Zoo and Wildlife Medicine (JZWM) is considered one of the major sources of information on the biology and veterinary aspects in the field. It stems from the founding premise of AAZV to share zoo animal medicine experiences. The Journal evolved from the long history of members producing case reports and the increased publication of free-ranging wildlife papers. The Journal accepts manuscripts of original research findings, case reports in the field of veterinary medicine dealing with captive and free-ranging wild animals, brief communications regarding clinical or research observations that may warrant publication. It also publishes and encourages submission of relevant editorials, reviews, special reports, clinical challenges, abstracts of selected articles and book reviews. The Journal is published quarterly, is peer reviewed, is indexed by the major abstracting services, and is international in scope and distribution. Areas of interest include clinical medicine, surgery, anatomy, radiology, physiology, reproduction, nutrition, parasitology, microbiology, immunology, pathology (including infectious diseases and clinical pathology), toxicology, pharmacology, and epidemiology.